View Older Stories View More Recent Stories

Dec 21, 2017 11:15AM US FDA Updates SYMBICORT Label with LABA Safety Class Revisions and Removes Boxed WARNING for Serious Asthma-Related Outcomes
Dec 18, 2017 07:06AM AstraZeneca (AZN) sNDA for TAGRISSO in NSCLC Accepted by FDA
Dec 18, 2017 07:00AM US FDA Accepts Regulatory Submission for TAGRISSO (Osimertinib) in 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer
Dec 10, 2017 05:45PM AstraZeneca’s CALQUENCE® (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukemia Trials
Dec 9, 2017 01:00PM AstraZeneca’s CALQUENCE® (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial
Dec 6, 2017 07:08AM AstraZeneca (AZN) to Highlight Its Commitment to Blood Cancers at ASH
Dec 6, 2017 07:00AM AstraZeneca to Highlight Its Commitment to Blood Cancers at the 2017 American Society of Hematology Annual Meeting
Nov 30, 2017 07:00AM Celebrity Trainer and Author Bob Harper Teams up with AstraZeneca to Connect with Fellow Heart Attack Survivors
Nov 15, 2017 07:01AM AstraZeneca (AZN) Granted FDA Aprproval for FASLODEX (fulvestrant) in Combination with Abemaciclib
Nov 15, 2017 07:00AM FASLODEX® (fulvestrant) Receives US FDA Approval for the Treatment of Advanced Breast Cancer in Combination with Abemaciclib
Nov 15, 2017 06:24AM AstraZeneca's (AZN) FASENRA Receives US FDA Approval For Severe Eosinophilic Asthma
Nov 14, 2017 07:02PM FASENRA (benralizumab) Receives US FDA Approval For Severe Eosinophilic Asthma
Nov 8, 2017 07:14AM AstraZeneca (AZN) Shares Scientific Updates from Its Extensive CVMD Portfolio at AHA
Nov 8, 2017 07:00AM AstraZeneca Shares Scientific Updates from Its Extensive Cardiovascular, Renal and Metabolic Diseases (CVMD) Portfolio at AHA 2017
Oct 31, 2017 06:20AM Incyte (INCY), AstraZeneca (AZN) Expand Clinical Trial Collaboration in Early Lung Cancer
Oct 31, 2017 03:00AM Incyte and AstraZeneca to Enter Clinical Trial Collaboration in Early Lung Cancer
Oct 23, 2017 07:06AM AstraZeneca (AZN) Says US FDA Approved New Easy-to-Use, Once-Weekly BYDUREON BCise Injectable Medicine for Patients with Type-2 Diabetes
Oct 23, 2017 07:00AM US FDA Approves New Easy-to-Use, Once-Weekly BYDUREON® BCise™ Injectable Medicine for Patients with Type-2 Diabetes
Oct 23, 2017 06:59AM Merck (MRK) & AstraZeneca PLC (AZN) Report Second Regulatory Submission to Rapidly Advance LYNPARZA (olaparib) in Japan
Oct 18, 2017 01:05PM AstraZeneca Announces New Data Showing US Preterm Infants at Significantly Greater Risk of RSV Hospitalizations Following 2014 Guidance Change
Oct 18, 2017 07:01AM Merck (MRK) and AstraZeneca (AZN) Granted FDA Acceptance of Regulatory Submission for LYNPARZA (Olaparib)
Oct 18, 2017 06:55AM US FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in Metastatic Breast Cancer and Grants Priority Review
Oct 17, 2017 07:04AM AstraZeneca (AZN) Reports FDA Acceptance of Supplemental Biologics License Application for IMFINZI (Durvalumab)
Oct 17, 2017 07:00AM US FDA Accepts Supplemental Biologics License Application for IMFINZI® (durvalumab) in Locally Advanced, Unresectable Non-Small Cell Lung Cancer
Oct 9, 2017 09:19AM AstraZeneca (AZN) Granted Breakthrough Therapy Designation by U.S. FDA for Tagrisso (Osimertinib)
Oct 9, 2017 09:14AM TAGRISSO® (osimertinib) Granted Breakthrough Therapy Designation by US FDA for the 1st-Line Treatment of Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
Sep 25, 2017 06:01AM NewLink Genetics (NLNK), AstraZeneca (AZN) Report Clinical Collaboration to Evaluate IO-Based Combination Therapies in Pancreatic Cancer
Sep 14, 2017 12:38PM Bydureon EXSCEL Trial Demonstrates Favorable Cardiovascular (CV) Safety Profile and Fewer CV Events in Patients with Type-2 Diabetes at Wide Range of CV Risk
Sep 11, 2017 05:42AM AstraZeneca (AZN) Reports TAGRISSO (osimertinib) Shows Potential as 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer
Sep 11, 2017 05:41AM AstraZeneca (AZN) Reports Superior Progression-Free Survival for IMFINZI (durvalumab) in the Pacific Trial
Sep 8, 2017 06:24PM AstraZeneca Presents Superior Progression-Free Survival for IMFINZI® (durvalumab) in the Pacific Trial of Patients with Locally-Advanced Unresectable Lung Cancer at ESMO 2017 Congress
Sep 8, 2017 06:24PM AstraZeneca’s TAGRISSO® (osimertinib) Shows Potential as a New Standard of Care in 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer at ESMO 2017 Congress
Sep 6, 2017 05:07PM Tezepelumab Significantly Reduced Asthma Exacerbations For A Broad Population Of Patients With Severe Uncontrolled Asthma
Aug 28, 2017 07:03AM AstraZeneca (AZN) Says FASLODEX Received US FDA Approval as Monotherapy for Expanded Use in HR+, HER2- Advanced Breast Cancer
Aug 28, 2017 07:00AM FASLODEX® (fulvestrant) Receives US FDA Approval as Monotherapy for Expanded Use in HR+, HER2- Advanced Breast Cancer
Aug 17, 2017 04:22PM LYNPARZA® (olaparib) Receives Additional FDA Approval in the US for Ovarian Cancer
Aug 17, 2017 03:38PM AstraZeneca (AZN), Merck (MRK) Confirm LYNPARZA Received Additional and Broad Approval in U.S. for Ovarian Cancer
Aug 1, 2017 07:17AM AstraZeneca (AZN) Receives Breakthrough Therapy Designation for Treatment of Patients with Mantle Cell Lymphoma
Aug 1, 2017 07:00AM Acalabrutinib Granted Breakthrough Therapy Designation by US FDA for the Treatment of Patients with Mantle Cell Lymphoma
Jul 31, 2017 07:05AM AstraZeneca (AZN) Says IMFINZI Granted Breakthrough Therapy Designation by US FDA for Patients with Locally Advanced Unresectable NSCLC
Jul 31, 2017 07:00AM IMFINZI™ (durvalumab) Granted Breakthrough Therapy Designation by US FDA for Patients with Locally Advanced Unresectable Non-Small Cell Lung Cancer
Jul 27, 2017 09:26AM Pre-Open Stock Movers 07/27: (CAPR) (SHOR) (FB) Higher; (CUR) (AZN) (CYH) Lower (more...)
Jul 27, 2017 07:35AM Tech, transports drag on Wall Street; Dow hits record
Jul 27, 2017 07:10AM AstraZeneca (AZN) Says TAGRISSO Significantly Improves Progression-Free Survival in Phase III FLAURA Trial for Lung Cancer
Jul 27, 2017 07:00AM TAGRISSO® (osimertinib) Significantly Improves Progression-Free Survival in the Phase III FLAURA Trial for Lung Cancer
Jun 29, 2017 03:44AM Chi-Med and AstraZeneca Initiate SAVOIR, a Global Phase III Trial of Savolitinib in Papillary Renal Cell Carcinoma
Jun 12, 2017 07:06AM AstraZeneca (AZN) Presents New Data on Safety Profile and Real-World CV Outcomes of Farxiga at ADA
Jun 12, 2017 07:00AM AstraZeneca Presents New Data Underpinning Safety Profile and Real-World CV Outcomes of Farxiga at ADA 2017
Jun 8, 2017 07:00AM AstraZeneca to Present Scientific Advances in Cardiovascular and Metabolic Diseases at 2017 ADA Scientific Sessions
Jun 6, 2017 07:00AM AstraZeneca Presents Tagrisso® (osimertinib) Data in Patients with EGFR T790M-Mutation Positive Lung Cancer and Central Nervous System Metastases
View More Recent Stories View Older Stories